SCHEDULE: Rosalind Funds Update Cellectar Biosciences Stake

Rosalind Advisors and affiliated funds disclose a 5.5% beneficial ownership in Cellectar Biosciences, Inc., factoring in conversion limitations.

Summary

• Rosalind Advisors, Inc., Steven Salamon, and Gilad Aharon each beneficially own 247,715 common shares of Cellectar Biosciences, Inc., representing 5.5% of the class.
• Rosalind Master Fund L.P. beneficially owns 185,036 common shares, representing 4.1% of the class.
• Rosalind Opportunities Fund I L.P. beneficially owns 62,678 common shares, representing 1.4% of the class.
• The reported percentages account for 'Preferred Stock Blockers' (9.99%) and 'Warrant Blockers' (4.99%) that limit conversion and exercise to prevent ownership exceeding these thresholds.
• The ownership percentages are calculated based on 4,240,134 shares of common stock outstanding as of November 10, 2025, as reported in the Issuer's 10-Q filed on November 13, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, confirming continued institutional investment without indicating any negative shifts or intent to influence control. The 'blocker' provisions are a structural detail rather than a direct sentiment indicator.

Positives

• Continued investment by institutional funds (Rosalind Advisors and affiliates) in Cellectar Biosciences, indicating ongoing investor interest.
• The filing confirms a passive investment strategy, with reporting persons certifying no intent to influence company control.

Negatives

• The presence of 'Blockers' on preferred stock and warrants suggests previous financing rounds included terms to prevent immediate significant dilution or control shifts, which could reflect past capital structure complexities.

Risks

• The 'Blockers' on preferred stock and warrants mean that the full potential conversion/exercise of these securities is currently restricted, which could impact future capital structure flexibility or the ability of these investors to increase their stake beyond the stated thresholds without triggering further disclosures or negotiations.

Future Outlook

No specific forward-looking statements or guidance from Cellectar Biosciences, Inc. are provided. This report primarily details a change in beneficial ownership by Rosalind Advisors and its affiliated funds.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors crossing certain ownership thresholds. For a biotechnology company like Cellectar Biosciences, the continued presence of institutional investors like Rosalind Advisors can signal ongoing investor confidence, even if the stake is passive. The 'blocker' provisions are common in early-stage or growth company financings to manage dilution and control.

Comparison to Industry Standards

• The 5.5% beneficial ownership stake by Rosalind Advisors and its principals is a significant, but passive, position for an institutional investor in a small-cap biotechnology company. This is generally in line with typical institutional investment strategies for companies in the development stage, where investors seek exposure without direct operational control.
• The use of 'blocker' provisions (9.99% for preferred stock, 4.99% for warrants) is a common mechanism in venture and growth equity financing to prevent an investor from inadvertently triggering beneficial ownership reporting requirements or hostile takeover rules, while still allowing for substantial investment. This practice is observed across various industries, particularly in those with volatile stock prices or complex capital structures.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and confirms a passive investment stance by Rosalind Advisors and its affiliates.
• Management: Confirms that a significant investor is not seeking to influence control, allowing management to continue executing its strategy without immediate activist pressure from this group.

Next Steps

• No specific future actions or milestones are mentioned in this beneficial ownership report.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of passive beneficial ownership and does not contain new information regarding Cellectar Biosciences' operational performance, financial health, or strategic direction. While it confirms continued institutional interest, it provides no basis for a change in investment thesis. Therefore, a 'hold' recommendation is appropriate for investors who have already established a position based on the company's fundamentals.

Keywords

Cellectar Biosciences, Rosalind Advisors, Schedule 13G, Beneficial Ownership, Common Shares, Biotechnology, Investment, SEC Filing, CLRB